For Immediate Release
March 14, 1996
NMAC Applauds FDA Approval of
New Antiretroviral AIDS Drug Crixivan
Washington, DC -- The National Minority AIDS Council (NMAC) applauds the FDA's swift approval of Crixivan, a new antiretroviral AIDS drug, produced by Merck & Co. Crixivan will become available on March 25 through a temporary special distribution system. However, patients and physicians will be able to call 1-800-927-8888, starting Monday, March 8 for information on receiving Crixivan.
The catalog price for the new drug will be $4,380 annually or $12 per day.
"The approval is extremely important to the survival of people living with HIV/AIDS," stated Moisés Agosto, Director of Treatment and Research Advocacy at NMAC. "We are especially pleased with the price points for Crixivan, which should make it more accessible and affordable for people of color living with AIDS. Merck's plans to insure ongoing availability of the drug for those who start taking it is also commendable."
"It is amazing how fast the FDA approval process has become and it shows a real commitment to the fight against HIV/AIDS," said Paul Kawata, NMAC's Executive Director. "We strongly urge people of color living with HIV/AIDS to contact their health care providers immediately to insure that they have access to this drug. It may be the most powerful weapon we have yet to see in this battle."
The National Minority AIDS Council (NMAC) is a national membership organization that represents over 600 community-based organizations. These frontlines organizations provide outreach, care, education, housing and support services to thousands of men and women in communities of color. NMAC provides visibility, leadership, educational messages, comprehensive technical assistance and most important a powerful national voice to these frontline AIDS workers.
For more information contact
National Minority AIDS Council
1931 13th Street, NW
Washington, DC 20009
Research and Treatment Advocacy Department